ReviewClinical drug investigation2016
Loxoprofen: A Review in Pain and Inflammation.
Review in Clinical drug investigation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 45 citations in OpenAlex.
- Effectiveness of Acupotomy Combined with Topical Diclofenac for Knee Osteoarthritis: A Randomized Controlled Trial.Journal of pain research · 2025Trial
- Trial
- Perioperative loxoprofen sodium is associated with lower pain and anxiety levels in dental implant surgery: a cohort study in China.Clinical oral investigations · 2026Article
- Granulation Methods and the Mechanisms for Improving Hardness of Loxoprofen Sodium Hydrate-Containing Tablets.Pharmaceutics · 2025Article
- Efficacy and safety of loxoprofen sodium cataplasms in the treatment of osteoarthritis: A randomized, multicenter study.Biomedical reports · 2025Article
- Diagnosis of acute Q fever using targeted next‑generation sequencing: A case report.Experimental and therapeutic medicine · 2025Article
- Population Pharmacokinetics of Loxoprofen and its alcoholic metabolites in healthy Korean men.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2024Article
- Efficacy and Safety of Loxoprofen Sodium Hydrogel Patch in Patients with Chronic Inflammatory Pain: A 4-Week Real-World Study.Journal of pain research · 2024Article
- Co-Delivery of Loxoprofen and Tofacitinib by Photothermal Microneedles for Rheumatoid Arthritis Treatment.Pharmaceutics · 2023Article
- Disproportionality analysis of acetaminophen-induced hepatic disorders with and without immune checkpoint inhibitors.International journal of clinical pharmacy · 2023Article
- Solubility Optimization of Loxoprofen as a Nonsteroidal Anti-Inflammatory Drug: Statistical Modeling and Optimization.Molecules (Basel, Switzerland) · 2022Article
- Anti-Inflammatory, Analgesic and Antioxidant Potential of New (2Molecules (Basel, Switzerland) · 2022Article
- Development of omega-3 loxoprofen-loaded nanoemulsion to limit the side effect associated with NSAIDs in treatment of tooth pain.Drug delivery · 2021Article
- Pharmacokinetics of loxoprofen in a self-administered overdose in a Japanese patient admitted to hospital.Journal of pharmaceutical health care and sciences · 2021Article
- The Anti-Inflammation and Anti-Nociception Effect of Ketoprofen in Rats Could Be Strengthened Through Co-Delivery of a HJournal of inflammation research · 2021Article
- Evaluation of the Percutaneous Absorption of Drug Molecules in Zebrafish.Molecules (Basel, Switzerland) · 2020Article
- Mechanism-Driven Read-Across of Chemical Hepatotoxicants Based on Chemical Structures and Biological Data.Toxicological sciences : an official journal of the Society of Toxicology · 2020Article
- Assessing Drug Interaction and Pharmacokinetics of Loxoprofen in Mice Treated with CYP3A Modulators.Pharmaceutics · 2019Article
- Exploring the Metabolism of Loxoprofen in Liver Microsomes: The Role of Cytochrome P450 and UDP-Glucuronosyltransferase in Its Biotransformation.Pharmaceutics · 2018Article
- Irreversible profound symptomatic bradycardia requiring pacemaker after tizanidine/loxoprofen combination therapy: a case report.The Journal of international medical research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Loxoprofen (Loxonin(®), Loxonin(®) Pap, Loxonin(®) Tape) is a prodrug-type NSAID that is available in several formulations, including 60 mg tablets, 100 mg hydrogel patches and 50 or 100 mg tape. In active comparator-controlled trials, oral loxoprofen therapy (ranging from 2 days to 6 weeks' duration depending on the pain type) provided analgesic efficacy that generally did not significantly differ from that of celecoxib for postoperative pain or frozen shoulder, ibuprofen for knee osteoarthritis or naproxen for lumbar pain. In double-blind, double-dummy, multicentre trials, loxoprofen hydrogel patches were noninferior to oral loxoprofen with regard to rates of final overall symptomatic improvement over 1-4 weeks in patients with knee osteoarthritis, myalgia or trauma-induced swelling and pain. Loxoprofen hydrogel patches were also noninferior to other commercially available patches (ketoprofen and indometacin) over 2 or 4 weeks in patients with knee osteoarthritis or myalgia in open-label studies. Oral and topical loxoprofen were generally well tolerated in clinical trials. Thus, loxoprofen is a useful analgesic option for patients with pain and inflammation, with topical loxoprofen potentially reducing the risk of gastrointestinal, cardiovascular and renal complications associated with oral NSAID use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.